BioPharmSignal logoBioPharmSignal

Biotech News

Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference

Neurocrine Biosciences (NBIX)Neurocrine BiosciencesConference / presentation

PWS-VISTA observational study will build longitudinal real-world evidence on VYKAT XR use for hyperphagia in Prader-Willi syndrome in routine clinical practice BRAVE-PWS observational study will capture caregiver-reported information to better understand the experience and burden of caring for

Related news

NBIXNeurocrine Biosciences2026-09-02 20:01 EST

Neurocrine Biosciences to Present at Upcoming Investor Conferences in September

NBIXNeurocrine Biosciences2026-08-12 12:30 EST

Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia

HRMYHarmony Biosciences2026-10-01 12:05 EST

Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days

HRMYHarmony Biosciences2026-09-03 12:05 EST

Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress

ABOSAcumen Pharmaceuticals2026-07-07 11:30 EST

Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026

XENEXenon2026-09-03 20:01 EST

Xenon to Present at Wells Fargo Healthcare Conference

CGTXCognition Therapeutics2026-09-08 11:30 EST

Cognition Therapeutics to Present at H.C. Wainwright Global Investment Conference

CLNNClene Inc.2026-08-17 12:30 EST

Clene to Present at the Emerging Growth Conference

CLNNClene Inc.2026-07-29 12:30 EST

Clene to Present at The Canaccord 46th Annual Growth Conference

GANXGain Therapeutics2026-09-29 21:50 EST

Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders

View all latest news

Neurocrine Biosciences

Neuroscience and Endocrinology Portfolio Neurocrine Biosciences discovers, develops and commercializes medicines for neuropsychiatric, neurological, endocrine and immunological disorders. Its business combines several first-in-class commercial products with a deep mid- and late-stage pipeline. Commercial Medicines The portfolio includes...

Recent company news

NBIXNeurocrine Biosciences2026-09-30 12:30 EST

Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference

NBIXNeurocrine Biosciences2026-09-28 20:05 EST

Neurocrine Biosciences Appoints Eiry W. Roberts, M.D., as Chief Medical Officer

NBIXNeurocrine Biosciences2026-09-02 20:01 EST

Neurocrine Biosciences to Present at Upcoming Investor Conferences in September

NBIXNeurocrine Biosciences2026-08-12 12:30 EST

Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia

NBIXNeurocrine Biosciences2026-08-07 12:30 EST

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist

Stock data

Close
140.71 USD
Market cap
15.57B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States